Vertex Pharmaceuticals presented promising data from clinical trials of its off-the-shelf stem cell therapy, zimislecel (formerly VX-880), for type 1 diabetes. The Phase 1/2 study showed that 10 out of 12 participants were able to discontinue insulin injections one year post-infusion. The therapy involves transplantation of lab-grown islet cells designed to produce insulin, potentially enabling durable glycemic control. Results unveiled at the American Diabetes Association meeting and published in the New England Journal of Medicine underscore the potential of cell therapies to transform diabetes management.